Xilio Therapeutics Inc (XLO) Stock Price, Quote & News

Company Profile

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 524 2466

Website: xiliotx.com

Address:

828 Winter Street, Suite 300, Waltham, United States

WallStWireAds Feb. 4 at 7:11 AM

$PPBT $JANX $XLO $BLRX >> After BMS’s $850M Bet on Tumor-Activated Immunotherapy, Investors Are Asking: Who’s Next? https://www.bioreview.com/after-bmss-850m-bet-on-tumor-activated-immunotherapy-investors-are-asking-whos-next/

2 · Reply

ezimon Feb. 3 at 5:27 PM

$XLO At some point this will be worth buying some shares, but currently we are not at that "some point" yet :-) If its good enough for management and BP to wait for delisting or RS then it is also good enough for me!

0 · Reply

AskSmacker Feb. 2 at 7:37 PM

$XLO Management appears to be planning ahead for key CMC milestones tied to upcoming IND submissions with the current job posting. https://job-boards.greenhouse.io/xiliotherapeutics/jobs/8326368002

2 · Reply

Jtlo Feb. 2 at 6:46 PM

$XLO historical trends point to february as movement. Let's see

0 · Reply

ezimon Feb. 2 at 5:23 PM

$XLO not yet, once it is delisted or reverse split announced

0 · Reply

AskSmacker Feb. 2 at 4:33 PM

$XLO this stock stinks along with management. Are we there yet?

2 · Reply

LesterDiamond99 Feb. 2 at 3:14 PM

$XLO Thays why you sell immediately.. When the ole Bio RS vote shows up in the email…Bios get zero Leash.

0 · Reply

LabPsycho Feb. 2 at 3:01 PM

$XLO @809trader IMO, One indicator of a bottom is when all the pumpers disappear and the previous lovers of a given stock start bashing it and the management. Wait a few months and for the trade volume and post volume on various platforms to dry up and price to plateau - then maybe thats the bottom. I expect XLO to bottom (temporarily) early April. Esp if a reverse split happens.

1 · Reply

ezimon Feb. 2 at 3:00 PM

$XLO is it $0.06 yet?

0 · Reply

809trader Jan. 31 at 1:28 PM

$XLO one thing I really like about this puppy is the lack of retail investor. There’s like 3 of us talking to each other and 2 of the 3 already sold lol and is even worst on X. Meanwhile big pharma and all stars bio funds keep adding to their position. The last round happening at 0.75 4 weeks ago. Also short interest dropping like is hot.

2 · Reply

Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates

Nov 13, 2025, 7:30 AM EST - 2 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

Nov 11, 2025, 4:04 AM EST - 3 months ago

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript

Nov 7, 2025, 9:05 AM EST - 3 months ago

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Nov 7, 2025, 9:01 AM EST - 3 months ago

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Nov 3, 2025, 4:30 PM EST - 3 months ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 30, 2025, 9:01 AM EDT - 3 months ago

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

Oct 3, 2025, 9:00 AM EDT - 4 months ago

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Sep 9, 2025, 7:30 AM EDT - 5 months ago

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

Aug 14, 2025, 7:30 AM EDT - 6 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

Jul 2, 2025, 4:30 PM EDT - 7 months ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 10, 2025, 4:30 PM EDT - 8 months ago

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

Jun 5, 2025, 6:38 PM EDT - 8 months ago

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Jun 2, 2025, 8:46 AM EDT - 8 months ago

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

Jun 2, 2025, 6:11 AM EDT - 8 months ago

Xilio Therapeutics Announces Proposed Public Offering

May 31, 2025, 8:00 AM EDT - 8 months ago

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

May 8, 2025, 7:30 AM EDT - 9 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 2, 2025, 4:30 PM EDT - 9 months ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 23, 2025, 4:30 PM EDT - 10 months ago

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

Mar 11, 2025, 7:30 AM EDT - 11 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 4:30 PM EST - 1 year ago

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 12, 2025, 10:44 AM EST - 1 year ago

Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?

Feb 12, 2025, 7:35 AM EST - 1 year ago

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Feb 12, 2025, 7:33 AM EST - 1 year ago

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Jan 21, 2025, 5:05 PM EST - 1 year ago

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

Jan 17, 2025, 4:30 PM EST - 1 year ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 19, 2024, 7:30 AM EST - 1 year ago

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Dec 16, 2024, 7:30 AM EST - 1 year ago

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

Nov 7, 2024, 9:15 AM EST - 1 year ago

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Nov 7, 2024, 9:05 AM EST - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

Oct 30, 2024, 9:01 AM EDT - 1 year ago

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 1 year ago

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Aug 28, 2024, 4:01 PM EDT - 1 year ago

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

Jun 13, 2024, 4:05 PM EDT - 1 year ago

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D.

May 14, 2024, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

Apr 1, 2024, 4:05 PM EDT - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

Mar 28, 2024, 7:05 AM EDT - 2 years ago

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Mar 28, 2024, 7:00 AM EDT - 2 years ago

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

GILD

Feb 28, 2024, 4:01 PM EST - 2 years ago

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

Jan 31, 2024, 4:01 PM EST - 2 years ago

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

Jan 8, 2024, 7:30 AM EST - 2 years ago

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

Dec 7, 2023, 7:30 AM EST - 2 years ago

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

Nov 9, 2023, 4:01 PM EST - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

Oct 31, 2023, 9:15 AM EDT - 2 years ago

Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting

Sep 27, 2023, 5:02 PM EDT - 2 years ago

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 5, 2023, 8:30 AM EDT - 2 years ago

Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D.

Sep 5, 2023, 7:30 AM EDT - 2 years ago

Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

Aug 14, 2023, 7:30 AM EDT - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results

WallStWireAds Feb. 4 at 7:11 AM

2 · Reply

ezimon Feb. 3 at 5:27 PM

0 · Reply

AskSmacker Feb. 2 at 7:37 PM

$XLO Management appears to be planning ahead for key CMC milestones tied to upcoming IND submissions with the current job posting. https://job-boards.greenhouse.io/xiliotherapeutics/jobs/8326368002

2 · Reply

Jtlo Feb. 2 at 6:46 PM

$XLO historical trends point to february as movement. Let's see

0 · Reply

ezimon Feb. 2 at 5:23 PM

$XLO not yet, once it is delisted or reverse split announced

0 · Reply

AskSmacker Feb. 2 at 4:33 PM

$XLO this stock stinks along with management. Are we there yet?

2 · Reply

LesterDiamond99 Feb. 2 at 3:14 PM

$XLO Thays why you sell immediately.. When the ole Bio RS vote shows up in the email…Bios get zero Leash.

0 · Reply

LabPsycho Feb. 2 at 3:01 PM

1 · Reply

ezimon Feb. 2 at 3:00 PM

$XLO is it $0.06 yet?

0 · Reply

809trader Jan. 31 at 1:28 PM

2 · Reply

809trader Jan. 30 at 10:36 PM

$XLO someone just got 99k shares at 0.6099 after hours. Probably another idiot like me :( 😂🥳

1 · Reply

809trader Jan. 30 at 4:29 PM

$XLO I have another order to buy 10k at 0.57 🥳🥳🥳🥳🥳 please baby Jesus let them sell it to me.

0 · Reply

ezimon Jan. 30 at 4:14 PM

$XLO I see no point in people worried about dilution or pink elephants!! within 2 months this is either getting delisted or goes through a RS. Why would warrant holders exercise now?

2 · Reply

LesterDiamond99 Jan. 29 at 4:04 PM

$XLO Out..minimal profit. Proxy vote emailed for reverse split.

0 · Reply

Skeetz99 Jan. 28 at 1:10 PM

$XLO Current O/S structure (per dilution tracker). Folks need to learn the difference between what is Outstanding vs what is Authorized. Very Low O/S structure in place right now which is great. What …is of any concern is the warrants and if exercised - then the Authorized shares go up which is significant dilution.

0 · Reply

809trader Jan. 27 at 9:43 PM

$XLO short interest continue to drop. Now only 2 million shares short. I never seen a company with this many shares outstanding plus warrants with only 2 million shares short. If you know about any other please tell me so I can buy it.

1 · Reply

LabPsycho Jan. 27 at 7:15 PM

$XLO @onemillion2012 @8AA Remember long ago I posted several concerns about XLO...notably the increase in authorized shares to a whopping 600 million! And their history of diluting big on any positive announcement. IMO current investors do not matter.

1 · Reply

onemillion2012 Jan. 27 at 6:16 PM

$BCAB another loser i got $XLO

0 · Reply

8AA Jan. 22 at 11:25 PM

$XLO fake price. which is not the price most people can make profit out of. only people in the know can make profit. market hit all time high and this shit is making all time low which is not looking good. guess people who buying this is just pure gamble at this point. buying lottery is much cheaper and safer.

1 · Reply

ThirstyFishy Jan. 22 at 9:17 PM

$XLO what is going on in after hours? Price is jumping all over, peaking at .91 for a short moment

1 · Reply

8AA Jan. 22 at 8:20 PM

$XLO turn out this stock has major seller and buyer. guess too risk to buy the stock full of insider trading.

1 · Reply

LabPsycho Jan. 22 at 4:46 PM

$XLO @809trader I think your below post with bullet points of owners is totally offset by investing in a company with a history of diluting massively on the way down. IMO reveals they care nothing about existing shareholders. Lets not forget the increase in authorized share to well over half a BILLION (with a B). Yuck. Ergo the 'reward' is likely limited in this case. Will be watching for any movement if / when this thing ever reverse splits. Good luck.

2 · Reply

Market Cap	40.18M
Revenue (ttm)	6.34M
Net Income (ttm)	-58.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-918.61%
Debt to Equity Ratio	0.00

Volume	266,249
Avg Vol	465,968
Day's Range	N/A - N/A
Shares Out	67.54M
Stochastic %K	19%
Beta	-0.06
Analysts	Sell
Price Target	$2.00